Literature DB >> 28470146

MicroRNA-520b Functions as a Tumor Suppressor in Colorectal Cancer by Inhibiting Defective in Cullin Neddylation 1 Domain Containing 1 (DCUN1D1).

Jing Xiao1, Guang Li2, Jingyu Zhou3, Shalong Wang3, Dongcai Liu3, Guoshun Shu3, Jianping Zhou3, Feng Ren3.   

Abstract

MicroRNAs (miRs), a class of small noncoding RNAs, are important regulators for gene expression through directly binding to the 3'-untranslated region (3'-UTR) of their target mRNA. Recently, downregulation of miR-520b has been observed in several common human cancers. However, the exact role of miR-520b in colorectal cancer (CRC) has not previously been studied. In this study, our data showed that miR-520b was significantly downregulated in CRC and cell lines when compared with adjacent normal tissues and a normal intestinal epithelial cell line. Low expression of miR-520b was notably associated with the malignant progress and a shorter survival time for CRC patients. Restoration of miR-520b inhibited cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) in CRC cells. Defective in cullin neddylation 1 domain containing 1 (DCUN1D1) was then identified as a novel target gene of miR-520b in CRC cells. The expression of DCUN1D1 was significantly increased in CRC, with a negative correlation to miR-520b expression in CRC tissues. Moreover, a high expression of DCUN1D1 was significantly associated with the malignant progress and a poor prognosis for CRC patients. Furthermore, overexpression of DCUN1D1 rescued the miR-520b-mediated malignant phenotypes and EMT in CRC cells. The data demonstrate that miR-520b functions as a tumor suppressor in CRC through targeting DCUN1D1, suggesting that miR-520b may become a potential therapeutic target for the treatment of CRC.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28470146     DOI: 10.3727/096504017X14920318811712

Source DB:  PubMed          Journal:  Oncol Res        ISSN: 0965-0407            Impact factor:   5.574


  8 in total

1.  Differential expression of microRNA between triple negative breast cancer patients of African American and European American descent.

Authors:  William M MacCuaig; Alexandra Thomas; Juan C Claros-Sorto; Jorge G Gomez-Gutierrez; Adam C Alexander; Elizabeth A Wellberg; William E Grizzle; Lacey R McNally
Journal:  Biotech Histochem       Date:  2022-01-04       Impact factor: 1.834

2.  Role of miR-520b in non-small cell lung cancer.

Authors:  Linlin Zhang; Shuangquan Yu
Journal:  Exp Ther Med       Date:  2018-09-12       Impact factor: 2.447

3.  Identification of microRNAs associated with the aggressiveness of prolactin pituitary tumors using bioinformatic analysis.

Authors:  Zihao Wang; Lu Gao; Xiaopeng Guo; Chenzhe Feng; Kan Deng; Wei Lian; Bing Xing
Journal:  Oncol Rep       Date:  2019-05-28       Impact factor: 3.906

4.  MiR-520b inhibits proliferation, migration and invasion in gallbladder carcinoma by targeting RAB22A.

Authors:  Jianpeng Zhou; Feng Gao; Hua Zhang; Mingxuan Xing; Zining Xu; Ruoyan Zhang
Journal:  Arch Med Sci       Date:  2019-11-11       Impact factor: 3.318

Review 5.  Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy.

Authors:  Xiaoli Hu; Jing Wang; Man Chu; Yi Liu; Zhi-Wei Wang; Xueqiong Zhu
Journal:  Mol Ther       Date:  2021-01-01       Impact factor: 11.454

6.  MLK3 is a newly identified microRNA-520b target that regulates liver cancer cell migration.

Authors:  Fei Zhang; Yu Zhu; Shuhua Wu; Guodong Hou; Nianxiang Wu; Lirun Qian; Dong Yang
Journal:  PLoS One       Date:  2020-03-26       Impact factor: 3.240

7.  Exosomal miR-1228 From Cancer-Associated Fibroblasts Promotes Cell Migration and Invasion of Osteosarcoma by Directly Targeting SCAI.

Authors:  Jian-Wei Wang; Xiao-Feng Wu; Xiao-Juan Gu; Xing-Hua Jiang
Journal:  Oncol Res       Date:  2018-08-08       Impact factor: 5.574

8.  The Potential Therapeutic Role of Exosomal MicroRNA-520b Derived from Normal Fibroblasts in Pancreatic Cancer.

Authors:  Huijuan Shi; Hui Li; Tiantian Zhen; Yu Dong; Xiaojuan Pei; Xiangliang Zhang
Journal:  Mol Ther Nucleic Acids       Date:  2020-01-10       Impact factor: 10.183

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.